Vassilopoulos G, Trobridge G, Josephson N C, Russell D W
Division of Hematology, University of Washington, Seattle, WA 98195, USA.
Blood. 2001 Aug 1;98(3):604-9. doi: 10.1182/blood.v98.3.604.
Gene transfer into hematopoietic stem cells (HSCs) is an ideal treatment strategy for many genetic and hematologic diseases. However, progress has been limited by the low HSC transduction rates obtained with retroviral vectors based on murine leukemia viruses. This study examined the potential of vectors derived from the nonpathogenic human foamy virus (HFV) to transduce human CD34(+) cells and murine HSCs. More than 80% of human hematopoietic progenitors present in CD34(+) cell preparations derived from cord blood were transduced by a single overnight exposure to HFV vector stocks. Mice that received transduced bone marrow cells expressed the vector-encoded transgene long term in all major hematopoietic cell lineages and in over 50% of cells in some animals. Secondary bone marrow transplants and integration site analysis confirmed that gene transfer occurred at the stem cell level. Transgene silencing was not observed. Thus vectors based on foamy viruses represent a promising approach for HSC gene therapy. (Blood. 2001;98:604-609)
将基因导入造血干细胞(HSC)是治疗多种遗传性和血液性疾病的理想策略。然而,基于鼠白血病病毒的逆转录病毒载体对HSC的转导率较低,限制了该领域的进展。本研究检测了源自非致病性人泡沫病毒(HFV)的载体转导人CD34(+)细胞和小鼠HSC的潜力。来自脐带血的CD34(+)细胞制剂中的人类造血祖细胞,单次过夜暴露于HFV载体储备液后,超过80%被转导。接受转导骨髓细胞的小鼠在所有主要造血细胞谱系中均长期表达载体编码的转基因,在某些动物中,超过50%的细胞表达该转基因。二次骨髓移植和整合位点分析证实基因转移发生在干细胞水平。未观察到转基因沉默现象。因此,基于泡沫病毒的载体是HSC基因治疗的一种有前景的方法。(《血液》。2001年;98:604 - 609)